Ruchira Sengupta, MD
Critical Care Medicine · Grand Rapids, MINPI 1669813259
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.7% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 26.9% of the total. 2025 is the largest year on record at $695, more than ten times the $52 reported in 2020.
Across 89 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$547
- GSK$397
- Regeneron Healthcare Solutions, Inc.$245
- Mylan Specialty L.p.$167
- Sanofi$156
- Inari Medical, Inc.$134
- plus $388 from 6 others
What the payments were for
- Food & beverage$1,86692%
- Education$1698%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $547 |
| GSK | 25 | $397 |
| Regeneron Healthcare Solutions, Inc. | 11 | $245 |
| Mylan Specialty L.p. | 9 | $167 |
| Sanofi | 7 | $156 |
| Inari Medical, Inc. | 1 | $134 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Boehringer Ingelheim | 4 | $82 |
| Johnson & Johnson | 1 | $81 |
| Insmed, Inc. | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,035 in reported general payments places this provider in the 80th percentile of 177 critical care medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $247,577 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 205 | $193,181 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 103 | $79,151 |
| EliquisApixaban | 28 | $23,358 |
| Spiriva RespimatTiotropium Bromide | 16 | $19,802 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 147 | $6,027 |
| Atrovent HfaIpratropium Bromide | 12 | $5,702 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,517 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $5,492 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,321 |
| Roflumilast | 30 | $2,210 |
| Ventolin HfaAlbuterol Sulfate | 20 | $2,185 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,537 |
| Azithromycin | 45 | $585 |
| Fluticasone Propionate | 17 | $507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $82 | $267,37935 claims |
| GSKTrelegy Ellipta | $397 | $193,181205 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $547 | $84,667118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 critical care medicine providers in Michigan.
Other critical care medicine in Grand Rapids
- Jeffery WiltGrand Rapids$10K
- Jason WellsGrand Rapids$8K
- Maximiliano Tamae KakazuGrand Rapids$7K
- Greg MarcoGrand Rapids$5K
- Joseph PitcherGrand Rapids$4K
- Noah JentzenGrand Rapids$2K
- Ghaleb KhirfanGrand Rapids$2K
- Kevin PattersonGrand Rapids$2K
- Malik KhanGrand Rapids$2K
- Kevin SwiatekGrand Rapids$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.